Drug Profile
Lead-212 conjugated NNV 003 - Nordic Nanovector/Orano Med
Alternative Names: 212Pb-labeled monoclonal antibody targeting CD37 - Orano Med/Nordic Nanovector; 212Pb-NNV003; Alpha 37; Anti-CD37 212Pb-ARC - Orano Med/Nordic Nanovector; Lead-212 conjugated anti-CD37 antibody - Orano Med/Nordic Nanovector; Targeted alpha therapy - Orano Med/Nordic NanovectorLatest Information Update: 22 Aug 2023
Price :
$50
*
At a glance
- Originator AREVA Med; Nordic Nanovector
- Developer Nordic Nanovector; Orano Med
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Lead radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Chronic lymphocytic leukaemia
- Suspended Burkitt's lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 22 Aug 2023 Preclinical trials in Chronic lymphocytic leukaemia in Norway (IV) (Orano Med pipeline, August 2023)
- 22 Aug 2023 Preclinical trials in Chronic lymphocytic leukaemia in USA (IV) (Orano Med pipeline, August 2023)
- 08 Mar 2022 Pharmacodynamics data from preclinical trial in Chronic lymphocytic leukaemia and Non-Hodkgin's lymphoma released by Nordic Nanovector